Evidence map›Paper›PMID 36173954›Full record

ArticlePloS one2022

Pooling samples to increase testing capacity with Xpert Xpress SARS-CoV-2 during the Covid-19 pandemic in Lao People's Democratic Republic.

Vibol Iem, Phonepadith Xangsayarath, Phonenaly Chittamany, Sakhone Suthepmany, Souvimone Siphanthong, Phimpha Paboriboune, Silaphet Somphavong, Kontogianni Konstantina, Jahangir A M Khan, Thomas Edwards and 4 more

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Vibol IemNational Tuberculosis Control Center, Vientiane, Lao People's Democratic Republic.ORCID 0000-0001-6155-1402
Phonepadith XangsayarathNational Center for Laboratory and Epidemiology, Vientiane, Lao People's Democratic Republic.
Phonenaly ChittamanyNational Tuberculosis Control Center, Vientiane, Lao People's Democratic Republic.
Sakhone SuthepmanyNational Tuberculosis Control Center, Vientiane, Lao People's Democratic Republic.
Souvimone SiphanthongNational Tuberculosis Control Center, Vientiane, Lao People's Democratic Republic.
Phimpha PaboribouneCenter of Infectiology Lao Christophe Mérieux, Vientiane, Lao People's Democratic Republic.
Silaphet SomphavongLao Association for Medical Laboratory Sciences, Vientiane, Lao People's Democratic Republic.
Kontogianni KonstantinaLiverpool School of Tropical Medicine, Liverpool, United Kingdom.ORCID 0000-0002-5353-3682
Jahangir A M KhanUniversity of Gothenburg, Health Economics and Policy Unit, School of Public Health and Community Medicine, Gothenburg, Sweden.
Thomas EdwardsLiverpool School of Tropical Medicine, Liverpool, United Kingdom.
Tom WingfieldLiverpool School of Tropical Medicine, Liverpool, United Kingdom.
Jacob CreswellStop TB Partnership, Innovations and Grants, Geneva, Switzerland.ORCID 0000-0002-4885-940X
Jose DominguezInstitut d'Investigació Germans Trias i Pujol, CIBER Enfermedades Respiratorias, and Universitat Autònoma de Barcelona, Spain.
Luis E CuevasLiverpool School of Tropical Medicine, Liverpool, United Kingdom.ORCID 0000-0002-6581-0587

Funding

Medical Research Council MR/V004832/1Medical Research Council MR/V028618/1Wellcome TrustWellcome Trust 209075/Z/17/Z
6 · The paper itself

Abstract

The COVID-19 pandemic created the need for large-scale testing of populations. However, most laboratories do not have sufficient testing capacity for mass screening. We evaluated pooled testing of samples, as a strategy to increase testing capacity in Lao PDR. Samples of consecutive patients were tested in pools of four using the Xpert Xpress SARS CoV-2 assay. Positive pools were confirmed by individual testing, and we describe the performance of the test and savings achieved. We also diluted selected positive samples to describe its effect on the assays CT values. 1,568 patients were tested in 392 pools of four. 361 (92.1%) pools were negative and 31 (7.9%) positive. 29/31 (93.5% (95%CI 77-99%) positive pools were confirmed by individual testing of the samples but, in 2/31 (6.5%) the four individual samples were negative, suggesting contamination. Pools with only one positive sample had higher CT values (lower RNA concentrations) than the respective individual samples, indicating a dilution effect, which suggested an increased risk of false negative results with dilutions >1:10. However, this risk may be low if the prevalence of infection is high, when pools are more likely to contain more than one positive sample. Pooling saved 67% of cartridges and substantially increased testing capacity. Pooling samples increased SARS-CoV-2 testing capacity and resulted in considerable cartridge savings. Given the need for high-volume testing, countries may consider implementation of pooling for SARS-CoV-2 screening.

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingHumansLaosPandemicsRNARNA

Identifiers

PMID36173954
PMCPMC9522287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.